{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:30:15Z","timestamp":1793827815551,"version":"4.6.1"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["T32 A T004094"],"award-info":[{"award-number":["T32 A T004094"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1 U54 GM104940"],"award-info":[{"award-number":["1 U54 GM104940"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40265-018-0946-y","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T10:19:06Z","timestamp":1531736346000},"page":"1113-1132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Centrally Acting Agents for Obesity: Past, Present, and Future"],"prefix":"10.1007","volume":"78","author":[{"given":"Ann A.","family":"Coulter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida J.","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1766-6111","authenticated-orcid":false,"given":"Frank L.","family":"Greenway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"issue":"1","key":"946_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.7326\/0003-4819-103-1-147","volume":"103","author":"Health implications of obesity","year":"1985","unstructured":"Health implications of obesity. National institutes of health consensus development conference statement. Ann Intern Med. 1985;103(1):147\u201351.","journal-title":"Ann Intern Med"},{"issue":"6505","key":"946_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/372425a0","volume":"372","author":"Y Zhang","year":"1994","unstructured":"Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425\u201332.","journal-title":"Nature"},{"issue":"1","key":"946_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.appet.2005.01.002","volume":"45","author":"DA Williamson","year":"2005","unstructured":"Williamson DA, Ravussin E, Wong ML, Wagner A, Dipaoli A, Caglayan S, et al. Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy. Appetite. 2005;45(1):75\u201380.","journal-title":"Appetite."},{"key":"946_CR4","doi-asserted-by":"crossref","unstructured":"Nathanson M. The Central Action of beta-aminopropylbenzene (Benzedrine) clinical observations. JAMA. 1937;108:528\u201331.","DOI":"10.1001\/jama.1937.02780070012004"},{"issue":"3","key":"946_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/j.1550-8528.1994.tb00061.x","volume":"2","author":"MF Lesses","year":"1994","unstructured":"Lesses MF, Myerson A. Human autonomic pharmacology. XVI. Benzedrine sulfate as an aid in the treatment of obesity. 1938. Obes Res. 1994;2(3):286\u201392.","journal-title":"Obes Res"},{"issue":"17","key":"946_CR6","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1001\/jama.1947.02880340022005","volume":"134","author":"SC Harris","year":"1947","unstructured":"Harris SC, Ivy AC, Searle LM. The mechanism of amphetamine-induced loss of weight; a consideration of the theory of hunger and appetite. J Am Med Assoc. 1947;134(17):1468\u201375.","journal-title":"J Am Med Assoc"},{"key":"946_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1146\/annurev.pharmtox.47.120505.105140","volume":"47","author":"AE Fleckenstein","year":"2007","unstructured":"Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681\u201398.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"946_CR8","volume-title":"Review of amphetamine-like drugs by the Food and Drug Administration","author":"BA Scoville","year":"1976","unstructured":"Scoville BA. Review of amphetamine-like drugs by the Food and Drug Administration. Washington: DC US Government Printing Office; 1976."},{"issue":"1","key":"946_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/thx.27.1.127","volume":"27","author":"E Byrne-Quinn","year":"1972","unstructured":"Byrne-Quinn E, Grover RF. Aminorex (Menocil) and amphetamine: acute and chronic effects on pulmonary and systemic haemodynamics in the calf. Thorax. 1972;27(1):127\u201331.","journal-title":"Thorax"},{"issue":"4","key":"946_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/00000441-200104000-00009","volume":"321","author":"ED Michelakis","year":"2001","unstructured":"Michelakis ED, Weir EK. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci. 2001;321(4):292\u20139.","journal-title":"Am J Med Sci"},{"key":"946_CR11","unstructured":"Gurtner HP. Pulmonary hypertension, \u201cplexogenic pulmonary arteriopathy\u201d and the appetite depressant drug aminorex: post or propter? Bull Eur Physiopathol Respir. 1979;15(5):897\u2013923."},{"issue":"5","key":"946_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/clpt.1992.68","volume":"51","author":"M Weintraub","year":"1992","unstructured":"Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther. 1992;51(5):581\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"946_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJM199608293350901","volume":"335","author":"L Abenhaim","year":"1996","unstructured":"Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609\u201316.","journal-title":"N Engl J Med"},{"issue":"9","key":"946_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"946_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1517\/14740330902931524","volume":"8","author":"RB Rothman","year":"2009","unstructured":"Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf. 2009;8(3):317\u201329.","journal-title":"Expert Opin Drug Saf."},{"issue":"6522","key":"946_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/374542a0","volume":"374","author":"LH Tecott","year":"1995","unstructured":"Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374(6522):542\u20136.","journal-title":"Nature"},{"issue":"4","key":"946_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/j.1550-8528.1999.tb00420.x","volume":"7","author":"F Greenway","year":"1999","unstructured":"Greenway F, Herber D, Raum W, Herber D, Morales S. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res. 1999;7(4):370\u20138.","journal-title":"Obes Res"},{"issue":"1 Suppl","key":"946_CR18","doi-asserted-by":"publisher","first-page":"203S","DOI":"10.1093\/ajcn\/55.1.203s","volume":"55","author":"FL Greenway","year":"1992","unstructured":"Greenway FL. Clinical studies with phenylpropanolamine: a metaanalysis. Am J Clin Nutr. 1992;55(1 Suppl):203S\u20135S.","journal-title":"Am J Clin Nutr"},{"issue":"25","key":"946_CR19","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1056\/NEJM200012213432501","volume":"343","author":"WN Kernan","year":"2000","unstructured":"Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826\u201332.","journal-title":"N Engl J Med"},{"key":"946_CR20","doi-asserted-by":"crossref","unstructured":"Domingue JN. Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology. 2007;69(3):320 (author reply -1).","DOI":"10.1212\/01.wnl.0000275291.02789.b3"},{"issue":"7","key":"946_CR21","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/oby.2007.205","volume":"15","author":"A Astrup","year":"2007","unstructured":"Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, et al. Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects. Obesity (Silver Spring). 2007;15(7):1717\u201331.","journal-title":"Obesity (Silver Spring)."},{"issue":"2","key":"946_CR22","first-page":"179","volume":"9","author":"J Simiand","year":"1998","unstructured":"Simiand J, Keane M, Keane PE, Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol. 1998;9(2):179\u201381.","journal-title":"Behav Pharmacol"},{"key":"946_CR23","doi-asserted-by":"crossref","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, Group RI-ES. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389\u201397.","DOI":"10.1016\/S0140-6736(05)66374-X"},{"issue":"10","key":"946_CR24","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.molmet.2017.06.010","volume":"6","author":"J Tam","year":"2017","unstructured":"Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, et al. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling. Mol Metab. 2017;6(10):1113\u201325.","journal-title":"Mol Metab."},{"key":"946_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2018.01.009","volume":"49","author":"J Tam","year":"2018","unstructured":"Tam J, Hinden L, Drori A, Udi S, Azar S, Baraghithy S. The therapeutic potential of targeting the peripheral endocannabinoid\/CB1 receptor system. Eur J Intern Med. 2018;49:23\u20139.","journal-title":"Eur J Intern Med."},{"issue":"9","key":"946_CR26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/oby.2003.152","volume":"11","author":"SH Kim","year":"2003","unstructured":"Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 2003;11(9):1116\u201323.","journal-title":"Obes Res"},{"key":"946_CR27","doi-asserted-by":"crossref","unstructured":"James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet. 2000;356(9248):2119-25.","DOI":"10.1016\/S0140-6736(00)03491-7"},{"issue":"10","key":"946_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WP James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905\u201317.","journal-title":"N Engl J Med"},{"issue":"69","key":"946_CR29","first-page":"26","volume":"13","author":"The amphetamine appetite suppressant saga","year":"2004","unstructured":"The amphetamine appetite suppressant saga. Prescrire Int. 2004;13(69):26\u20139.","journal-title":"Prescrire Int."},{"key":"946_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-193002000-00001","volume":"9","author":"K Chen","year":"1930","unstructured":"Chen K. Ephedrine and related substances. Medicine. 1930;9:1\u2013119.","journal-title":"Medicine."},{"issue":"3","key":"946_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.1467-789x.2001.00038.x","volume":"2","author":"FL Greenway","year":"2001","unstructured":"Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev. 2001;2(3):199\u2013211.","journal-title":"Obes Rev"},{"issue":"25","key":"946_CR32","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJM200012213432502","volume":"343","author":"CA Haller","year":"2000","unstructured":"Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343(25):1833\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"946_CR33","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.289.12.1537","volume":"289","author":"PG Shekelle","year":"2003","unstructured":"Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289(12):1537\u201345.","journal-title":"JAMA"},{"issue":"12","key":"946_CR34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/obr.12606","volume":"18","author":"Z Dong","year":"2017","unstructured":"Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obes Rev. 2017;18(12):1377\u201385.","journal-title":"Obes Rev"},{"issue":"5588","key":"946_CR35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","volume":"1","author":"JF Munro","year":"1968","unstructured":"Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1(5588):352\u20134.","journal-title":"Br Med J"},{"issue":"5","key":"946_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nn1455","volume":"8","author":"RD Cone","year":"2005","unstructured":"Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571\u20138.","journal-title":"Nat Neurosci"},{"issue":"1","key":"946_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30\u20139.","journal-title":"Obesity (Silver Spring)."},{"issue":"12","key":"946_CR38","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1210\/jc.2009-1350","volume":"94","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94(12):4898\u2013906.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"946_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/dom.12095","volume":"15","author":"SR Smith","year":"2013","unstructured":"Smith SR, Fujioka K, Gupta AK, Billes SK, Burns C, Kim D, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab. 2013;15(9):863\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"9741","key":"946_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled. Phase III trial. Lancet. 2010;376(9741):595\u2013605.","journal-title":"Lancet"},{"issue":"5","key":"946_CR41","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, Phase III trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935\u201343.","journal-title":"Obesity (Silver Spring)."},{"issue":"1","key":"946_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O\u2019Neil PM, et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110\u201320.","journal-title":"Obesity (Silver Spring)."},{"issue":"12","key":"946_CR43","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022\u20139.","journal-title":"Diabetes Care"},{"key":"946_CR44","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.12m01494","author":"SL McElroy","year":"2013","unstructured":"McElroy SL, Guerdjikova AI, Kim DD, Burns C, Harris-Collazo R, Landbloom R, et al. Naltrexone\/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. Prim Care Companion CNS Disord. 2013. https:\/\/doi.org\/10.4088\/PCC.12m01494 .","journal-title":"Prim Care Companion CNS Disord."},{"issue":"5","key":"946_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/cob.12108","volume":"5","author":"RL Kolotkin","year":"2015","unstructured":"Kolotkin RL, Chen S, Klassen P, Gilder K, Greenway FL. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone\/bupropion for obesity. Clin Obes. 2015;5(5):237\u201344.","journal-title":"Clin Obes."},{"issue":"5","key":"946_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cob.12157","volume":"6","author":"K Hong","year":"2016","unstructured":"Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP. Naltrexone\/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes. 2016;6(5):305\u201312.","journal-title":"Clin Obes."},{"issue":"8","key":"946_CR47","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/ijo.2017.89","volume":"41","author":"M Dalton","year":"2017","unstructured":"Dalton M, Finlayson G, Walsh B, Halseth AE, Duarte C, Blundell JE. Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample. Int J Obes (Lond). 2017;41(8):1232\u20136.","journal-title":"Int J Obes (Lond)."},{"key":"946_CR48","unstructured":"2017 [cited; Contrave Prescribing Instructions]. https:\/\/contrave.com\/wp-content\/uploads\/2017\/05\/Contrave_PI.pdf . Accessed 16 Feb 2018."},{"issue":"10","key":"946_CR49","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990\u20131004.","journal-title":"JAMA"},{"issue":"9","key":"946_CR50","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/ijo.2016.67","volume":"40","author":"K Fujioka","year":"2016","unstructured":"Fujioka K, Plodkowski R, O\u2019Neil PM, Gilder K, Walsh B, Greenway FL. The relationship between early weight loss and weight loss at 1\u00a0year with naltrexone ER\/bupropion ER combination therapy. Int J Obes (Lond). 2016;40(9):1369\u201375.","journal-title":"Int J Obes (Lond)."},{"issue":"4","key":"946_CR51","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bph.12338","volume":"170","author":"CP Coomans","year":"2013","unstructured":"Coomans CP, Geerling JJ, van den Berg SA, van Diepen HC, Garcia-Tardon N, Thomas A, et al. The insulin sensitizing effect of topiramate involves KATP channel activation in the central nervous system. Br J Pharmacol. 2013;170(4):908\u201318.","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"946_CR52","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","volume":"41","author":"HS White","year":"2000","unstructured":"White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(Suppl 1):S17\u201320.","journal-title":"Epilepsia."},{"issue":"Suppl 1","key":"946_CR53","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","volume":"41","author":"JW Gibbs 3rd","year":"2000","unstructured":"Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41(Suppl 1):S10\u20136.","journal-title":"Epilepsia."},{"issue":"9","key":"946_CR54","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/oby.2000.84","volume":"8","author":"F Picard","year":"2000","unstructured":"Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa\/?) and obese (fa\/fa) Zucker rats. Obes Res. 2000;8(9):656\u201363.","journal-title":"Obes Res"},{"issue":"3","key":"946_CR55","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.ijo.0801873","volume":"26","author":"D Richard","year":"2002","unstructured":"Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord. 2002;26(3):344\u201353.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"4","key":"946_CR56","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/oby.2003.78","volume":"11","author":"E Ben-Menachem","year":"2003","unstructured":"Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003;11(4):556\u201362.","journal-title":"Obes Res"},{"issue":"6","key":"946_CR57","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/oby.2003.102","volume":"11","author":"GA Bray","year":"2003","unstructured":"Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722\u201333.","journal-title":"Obes Res"},{"issue":"11","key":"946_CR58","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"LJ Aronne","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163\u201371.","journal-title":"Obesity (Silver Spring)."},{"issue":"9774","key":"946_CR59","first-page":"1341","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled. Phase III trial. Lancet. 2011;377(9774):1341\u201352.","journal-title":"Phase III trial. Lancet."},{"issue":"2","key":"946_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, Phase III extension study. Am J Clin Nutr. 2012;95(2):297\u2013308.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"946_CR61","doi-asserted-by":"publisher","first-page":"912","DOI":"10.2337\/dc13-1518","volume":"37","author":"WT Garvey","year":"2014","unstructured":"Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37(4):912\u201321.","journal-title":"Diabetes Care"},{"issue":"12","key":"946_CR62","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.2337\/dc14-0930","volume":"37","author":"WT Garvey","year":"2014","unstructured":"Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37(12):3309\u201316.","journal-title":"Diabetes Care"},{"issue":"2","key":"946_CR63","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330\u201342.","journal-title":"Obesity (Silver Spring)."},{"issue":"11","key":"946_CR64","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.5665\/sleep.2204","volume":"35","author":"DH Winslow","year":"2012","unstructured":"Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35(11):1529\u201339.","journal-title":"Sleep"},{"issue":"10","key":"946_CR65","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/pds.3612","volume":"23","author":"D Mines","year":"2014","unstructured":"Mines D, Tennis P, Curkendall SM, Li DK, Peterson C, Andrews EB, et al. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf. 2014;23(10):1017\u201325.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"946_CR66","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s11136-015-1153-x","volume":"25","author":"RL Kolotkin","year":"2016","unstructured":"Kolotkin RL, Gadde KM, Peterson CA, Crosby RD. Health-related quality of life in two randomized controlled trials of phentermine\/topiramate for obesity: What mediates improvement? Qual Life Res. 2016;25(5):1237\u201344.","journal-title":"Qual Life Res"},{"issue":"2","key":"946_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40801-015-0021-x","volume":"2","author":"J Li","year":"2015","unstructured":"Li J, Reaven NL, Funk SE, McGaughey K, Neovius M. 4-year cost trajectories in real-world patients matched to the metabolic profiles of trial subjects before\/after treatment with phentermine-topiramate. Drugs Real World Outcomes. 2015;2(2):143\u201351.","journal-title":"Drugs Real World Outcomes."},{"issue":"7","key":"946_CR68","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40273-014-0182-6","volume":"33","author":"EA Finkelstein","year":"2015","unstructured":"Finkelstein EA, Kruger E, Karnawat S. Cost-effectiveness analysis of qsymia for weight loss. Pharmacoeconomics. 2015;33(7):699\u2013706.","journal-title":"Pharmacoeconomics."},{"issue":"3","key":"946_CR69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0163-7258(98)00019-9","volume":"79","author":"BL Roth","year":"1998","unstructured":"Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther. 1998;79(3):231\u201357.","journal-title":"Pharmacol Ther"},{"key":"946_CR70","unstructured":"[cited; http:\/\/www.diabetesincontrol.com\/fda-approves-lorcaserin-belviq-for-treatment-of-obesity\/ . Accessed 16 Feb 2018."},{"issue":"3","key":"946_CR71","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/oby.2008.537","volume":"17","author":"SR Smith","year":"2009","unstructured":"Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, et al. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring). 2009;17(3):494\u2013503.","journal-title":"Obesity (Silver Spring)."},{"issue":"3","key":"946_CR72","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245\u201356.","journal-title":"N Engl J Med"},{"issue":"10","key":"946_CR73","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1210\/jc.2011-1256","volume":"96","author":"MC Fidler","year":"2011","unstructured":"Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067\u201377.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"946_CR74","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/oby.2012.66","volume":"20","author":"PM O\u2019Neil","year":"2012","unstructured":"O\u2019Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426\u201336.","journal-title":"Obesity (Silver Spring)."},{"issue":"10","key":"946_CR75","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/oby.20841","volume":"22","author":"SR Smith","year":"2014","unstructured":"Smith SR, O\u2019Neil PM, Astrup A, Finer N, Sanchez-Kam M, Fraher K, et al. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring). 2014;22(10):2137\u201346.","journal-title":"Obesity (Silver Spring)."},{"issue":"5","key":"946_CR76","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/clpt.2011.20","volume":"89","author":"MJ Shram","year":"2011","unstructured":"Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther. 2011;89(5):683\u201392.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"946_CR77","first-page":"994","volume":"19","author":"RT Hurt","year":"2017","unstructured":"Hurt RT, Croghan IT, Schroeder DR, Hays JT, Choi DS, Ebbert JO. Combination varenicline and lorcaserin for tobacco dependence treatment and weight gain prevention in overweight and obese smokers: a pilot study. Nicotine Tob Res. 2017;19(8):994\u20138.","journal-title":"Nicotine Tob Res"},{"issue":"5","key":"946_CR78","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/oby.21811","volume":"25","author":"SR Smith","year":"2017","unstructured":"Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, et al. Coadministration of lorcaserin and phentermine for weight management: a 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017;25(5):857\u201365.","journal-title":"Obesity (Silver Spring)."},{"issue":"2","key":"946_CR79","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/oby.22094","volume":"26","author":"CJ Rebello","year":"2018","unstructured":"Rebello CJ, Nikonova EV, Zhou S, Aronne LJ, Fujioka K, Garvey WT, et al. Effect of lorcaserin alone and in combination with phentermine on food cravings after 12-week treatment: a randomized substudy. Obesity (Silver Spring). 2018;26(2):332\u20139.","journal-title":"Obesity (Silver Spring)."},{"issue":"10","key":"946_CR80","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2337\/db16-0635","volume":"65","author":"OM Farr","year":"2016","unstructured":"Farr OM, Upadhyay J, Gavrieli A, Camp M, Spyrou N, Kaye H, et al. Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: a 4-week-long randomized, placebo-controlled. Double-blind clinical trial. Diabetes. 2016;65(10):2943\u201353.","journal-title":"Diabetes"},{"issue":"3","key":"946_CR81","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1210\/jc.2010-1848","volume":"96","author":"CK Martin","year":"2011","unstructured":"Martin CK, Redman LM, Zhang J, Sanchez M, Anderson CM, Smith SR, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96(3):837\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"946_CR82","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1080\/00325481.2016.1178590","volume":"128","author":"R Nesto","year":"2016","unstructured":"Nesto R, Fain R, Li Y, Shanahan W. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgrad Med. 2016;128(4):364\u201370.","journal-title":"Postgrad Med"},{"issue":"6","key":"946_CR83","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/cob.12207","volume":"7","author":"RL Kolotkin","year":"2017","unstructured":"Kolotkin RL, Crosby RD, Wang Z. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement? Clin Obes. 2017;7(6):347\u201353.","journal-title":"Clin Obes."},{"issue":"1","key":"946_CR84","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/oby.21695","volume":"25","author":"NJ Weissman","year":"2017","unstructured":"Weissman NJ, Smith SR, Fain R, Hall N, Shanahan WR. Effects of lorcaserin on pre-existing valvulopathy: a pooled analysis of Phase III trials. Obesity (Silver Spring). 2017;25(1):39\u201344.","journal-title":"Obesity (Silver Spring)."},{"issue":"9","key":"946_CR85","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1172\/JCI93362","volume":"127","author":"CC Lord","year":"2017","unstructured":"Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017;127(9):3402\u20136.","journal-title":"J Clin Invest."},{"issue":"8","key":"946_CR86","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/17425255.2017.1344214","volume":"13","author":"KM Hurren","year":"2017","unstructured":"Hurren KM, Dunham MW. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. Expert Opin Drug Metab Toxicol. 2017;13(8):891\u20136.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"4","key":"946_CR87","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.beem.2009.03.008","volume":"23","author":"S Madsbad","year":"2009","unstructured":"Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)\u2013preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009;23(4):463\u201377.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"946_CR88","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","volume":"221","author":"L van Bloemendaal","year":"2014","unstructured":"van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221(1):T1\u201316.","journal-title":"J Endocrinol"},{"issue":"9701","key":"946_CR89","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606\u201316.","journal-title":"Lancet"},{"issue":"6","key":"946_CR90","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2\u00a0years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843\u201354.","journal-title":"Int J Obes (Lond)."},{"issue":"1","key":"946_CR91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"10077","key":"946_CR92","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3\u00a0years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409.","journal-title":"Lancet"},{"issue":"11","key":"946_CR93","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443\u201351.","journal-title":"Int J Obes (Lond)."},{"issue":"7","key":"946_CR94","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399.","journal-title":"JAMA"},{"issue":"8","key":"946_CR95","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0\u00a0mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310\u20139.","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"946_CR96","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dom.13125","volume":"20","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20(3):734\u201339.","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"946_CR97","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2337\/dc16-2747","volume":"40","author":"WM Steinberg","year":"2017","unstructured":"Steinberg WM, Buse JB, Ghorbani MLM, Orsted DD, Nauck MA, Committee LS, et al. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diabetes Care. 2017;40(7):966\u201372.","journal-title":"Diabetes Care"},{"key":"946_CR98","doi-asserted-by":"crossref","unstructured":"Kolotkin RL, Gabriel Smolarz B, Meincke HH, Fujioka K. Improvements in health-related quality of life over 3\u00a0years with liraglutide 3.0\u00a0mg compared with placebo in participants with overweight or obesity. Clin Obes. 2018;8(1):1\u201310.","DOI":"10.1111\/cob.12226"},{"issue":"6","key":"946_CR99","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1159\/000478099","volume":"10","author":"C le Roux","year":"2017","unstructured":"le Roux C, Aroda V, Hemmingsson J, Cancino AP, Christensen R, Pi-Sunyer X. Comparison of efficacy and safety of liraglutide 3.0\u00a0mg in individuals with BMI above and below 35\u00a0kg\/m2: a post hoc analysis. Obes Facts. 2017;10(6):531\u201344.","journal-title":"Obes Facts."},{"issue":"4","key":"946_CR100","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/dom.12632","volume":"18","author":"J Ard","year":"2016","unstructured":"Ard J, Cannon A, Lewis CE, Lofton H, Vang Skjoth T, Stevenin B, et al. Efficacy and safety of liraglutide 3.0\u00a0mg for weight management are similar across races: subgroup analysis across the SCALE and Phase II randomized trials. Diabetes Obes Metab. 2016;18(4):430\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"946_CR101","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","volume":"19","author":"PM O\u2019Neil","year":"2017","unstructured":"O\u2019Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, et al. Neuropsychiatric safety with liraglutide 3.0\u00a0mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19(11):1529\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"946_CR102","doi-asserted-by":"crossref","unstructured":"Fujioka K, O\u2019Neil PM, Davies M, Greenway F, D CWL, Claudius B, et al. Early weight loss with liraglutide 3.0\u00a0mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring). 2016;24(11):2278-88.","DOI":"10.1002\/oby.21629"},{"issue":"12","key":"946_CR103","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S2468-1253(17)30285-6","volume":"2","author":"H Halawi","year":"2017","unstructured":"Halawi H, Khemani D, Eckert D, O\u2019Neill J, Kadouh H, Grothe K, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890\u20139.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"7","key":"946_CR104","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-015-1868-1","volume":"71","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Pirs B, Goricar K, Dolzan V, Janez A. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol. 2015;71(7):817\u201324.","journal-title":"Eur J Clin Pharmacol"},{"key":"946_CR105","doi-asserted-by":"crossref","unstructured":"Robert SA, Rohana AG, Shah SA, Chinna K, Wan Mohamud WN, Kamaruddin NA. Improvement in binge eating in non-diabetic obese individuals after 3\u00a0months of treatment with liraglutide\u2014a pilot study. Obes Res Clin Pract. 2015;9(3):301-4.","DOI":"10.1016\/j.orcp.2015.03.005"},{"issue":"10","key":"946_CR106","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1475-2840-10-109","volume":"1","author":"K Inoue","year":"2011","unstructured":"Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 2011;1(10):109.","journal-title":"Cardiovasc Diabetol."},{"issue":"8","key":"946_CR107","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1210\/jc.2015-1176","volume":"100","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jorgensen NR, et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 2015;100(8):2909\u201317.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"946_CR108","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","volume":"17","author":"V Lambadiari","year":"2018","unstructured":"Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, et al. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):8.","journal-title":"Cardiovasc Diabetol."},{"issue":"7","key":"946_CR109","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(7):719\u201328.","journal-title":"JAMA Psychiatry."},{"key":"946_CR110","unstructured":"FDA. 2014 [cited; Liraglutide label]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321Orig1s000lbl.pdf . Accessed 16 Feb 2018."},{"issue":"4","key":"946_CR111","first-page":"178","volume":"10","author":"KL Tran","year":"2017","unstructured":"Tran KL, Park YI, Pandya S, Muliyil NJ, Jensen BD, Huynh K, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178\u201388.","journal-title":"Am Health Drug Benefits."},{"issue":"3","key":"946_CR112","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S2213-8587(17)30236-X","volume":"6","author":"DH Bessesen","year":"2018","unstructured":"Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6(3):237\u201348.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"946_CR113","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/sj.bjp.0707539","volume":"153","author":"T Lehr","year":"2008","unstructured":"Lehr T, Staab A, Tillmann C, Nielsen EO, Trommeshauser D, Schaefer HG, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol. 2008;153(1):164\u201374.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"946_CR114","first-page":"1592","volume":"2","author":"U Thatte","year":"2001","unstructured":"Thatte U. NS-2330 (Neurosearch). Curr Opin Investig Drugs. 2001;2(11):1592\u20134.","journal-title":"Curr Opin Investig Drugs"},{"issue":"3","key":"946_CR115","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mds.21258","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson\u2019s disease. Mov Disord. 2007;22(3):359\u201365.","journal-title":"Mov Disord"},{"issue":"6","key":"946_CR116","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/oby.2008.56","volume":"16","author":"A Astrup","year":"2008","unstructured":"Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson\u2019s or Alzheimer\u2019s disease. Obesity (Silver Spring). 2008;16(6):1363\u20139.","journal-title":"Obesity (Silver Spring)."},{"issue":"9653","key":"946_CR117","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/S0140-6736(08)61525-1","volume":"372","author":"A Astrup","year":"2008","unstructured":"Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906\u201313.","journal-title":"Lancet"},{"issue":"7","key":"946_CR118","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/npp.2010.16","volume":"35","author":"AM Axel","year":"2010","unstructured":"Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010;35(7):1464\u201376.","journal-title":"Neuropsychopharmacology."},{"key":"946_CR119","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pbb.2013.07.018","volume":"110","author":"HH Hansen","year":"2013","unstructured":"Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacol Biochem Behav. 2013;110:265\u201371.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"946_CR120","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euroneuro.2013.10.007","volume":"24","author":"L Appel","year":"2014","unstructured":"Appel L, Bergstrom M, Buus Lassen J, Langstrom B. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol. 2014;24(2):251\u201361.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"946_CR121","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/ijo.2010.87","volume":"34","author":"A Sjodin","year":"2010","unstructured":"Sjodin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34(11):1634\u201343.","journal-title":"Int J Obes (Lond)."},{"issue":"3","key":"946_CR122","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/oby.2011.197","volume":"20","author":"JA Gilbert","year":"2012","unstructured":"Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjodin A. The effect of tesofensine on appetite sensations. Obesity (Silver Spring). 2012;20(3):553\u201361.","journal-title":"Obesity (Silver Spring)."},{"issue":"1","key":"946_CR123","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/clpt.2010.67","volume":"88","author":"KA Schoedel","year":"2010","unstructured":"Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010;88(1):69\u201378.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"946_CR124","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/oby.20122","volume":"21","author":"BH Bentzen","year":"2013","unstructured":"Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring). 2013;21(5):985\u201392.","journal-title":"Obesity (Silver Spring)."},{"issue":"9","key":"946_CR125","first-page":"891","volume":"376","author":"SP Marso","year":"2017","unstructured":"Marso SP, Holst AG, Vilsboll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376(9):891\u20132.","journal-title":"N Engl J Med"},{"issue":"15","key":"946_CR126","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460\u201370.","journal-title":"JAMA"},{"issue":"3","key":"946_CR127","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/NEJMoa1512693","volume":"375","author":"P Kuhnen","year":"2016","unstructured":"Kuhnen P, Clement K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240\u20136.","journal-title":"N Engl J Med"},{"key":"946_CR128","volume-title":"Letter on corpulence, addressed to the public","author":"W Banting","year":"1863","unstructured":"Banting W. Letter on corpulence, addressed to the public. London: Harris and Sons; 1863."},{"issue":"9123","key":"946_CR129","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sjostrom","year":"1998","unstructured":"Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167\u201372.","journal-title":"Lancet"},{"issue":"2","key":"946_CR130","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1081\/ERC-200027356","volume":"30","author":"R Sari","year":"2004","unstructured":"Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res. 2004;30(2):159\u201367.","journal-title":"Endocr Res"},{"issue":"5","key":"946_CR131","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/dc16-2427","volume":"40","author":"P Hollander","year":"2017","unstructured":"Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40(5):632\u20139.","journal-title":"Diabetes Care"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0946-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0946-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0946-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T15:49:27Z","timestamp":1693756167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0946-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":131,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0946-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"16 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Frank Greenway has served on the advisory boards for BAROnova, Eisai Inc., Curves, Novo Nordisk, Microbiome Therapeutics, Orexigen, Pamlab, PlenSat, Zaluvida and Zafgen. He has consulted for Basic Research, General Nutrition Corporation, Neothetics, Takeda, and Tech Enterprises.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}